Key result
Adjunctive tirofiban cuts periprocedural MI ~59% versus conventional therapy in elective PCI.
Why the study?
Does intravenous tirofiban reduce periprocedural myocardial infarction in stable angina patients undergoing elective PCI for long lesions with overlapping stents?
RCT (n=748)
Randomized
Yes
Does intravenous tirofiban reduce periprocedural myocardial infarction in stable angina patients undergoing elective PCI for long lesions with overlapping stents?
Effect estimate: OR 0.41 (95% CI 0.28-0.81)
Absolute Event Rate: 4% vs 11.5%
p-value: p=<0.001
Adjunctive use of intravenous tirofiban reduces periprocedural MI and 1-year MACE in stable angina patients undergoing elective PCI for long lesions with overlapping stents, without increasing major bleeding.
No takes yet. Share an insight, caveat, or question.
Supports adjunctive tirofiban in elective PCI for long lesions; extends prior evidence to overlapping stents.
Zhang et al. (2015) conducted an RCT in Stable coronary artery disease (n=748). Tirofiban vs. Conventional therapy was evaluated on Periprocedural myocardial infarction (PMI), defined as an elevation in CK-MB > 3 times the upper limit of normal 12 hr after the index procedure (OR 0.41, 95% CI 0.28-0.81, p=<0.001). Adjunctive use of tirofiban significantly reduced periprocedural myocardial infarction compared to conventional therapy (4.0% vs. 11.5%; OR 0.41; 95% CI 0.28-0.81; P<0.001) in elective PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: